GlassScriptPhysician profile
Heeeun Kang
NPI 1003159781
$415.83
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $107 · 2021: $32.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $71.53 | 2019-2021 | |
| Pfizer INC. | $69.52 | 2019-2020 | |
| Astellas Pharma US INC | $42.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.50 | 2019 | |
| Amgen INC. | $40.29 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.90 | 2019 | |
| Sanofi Pasteur INC. | $24.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.81 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.05 | 2021 | |
| Glaxosmithkline, LLC. | $13.08 | 2020 | |
| Merck Sharp & Dohme LLC | $13.03 | 2019 | |
| Lilly USA, LLC | $11.61 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heeeun Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.